The unexpected lower levels of HbT in the most aggressive breast cancer histologies have been confirmed by ex vivo complementary analysis, which assessed a reduction of Hb concentrations in the same mouse model of invasive carcinoma. The gene discussed is GSTM1; the disease is breast carcinoma.